Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-1241 in Presumed NASH
NCT06054815Phase 2Completed
- Sponsor
- NeuroBo Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vanoglipel in Nonalcoholic steatohepatitis (NASH), sponsored by NeuroBo Pharmaceuticals. Started Sep 2023; status: completed.
02
Drugs
vanoglipel
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06054815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054815.